Skip to content

Routine Versus Symptomatic Protein Pump Inhibitor Therapy for Prevention of Gastroesophageal Reflux After Per Oral Endoscopic Myotomy for Esophageal Achalasia

Routine Versus Symptomatic Protein Pump Inhibitor Therapy for Prevention of Gastroesophageal Reflux After Per Oral Endoscopic Myotomy for Esophageal Achalasia. Randomized Open-label Clinical Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05899842
Acronym
IPPOEM
Enrollment
132
Registered
2023-06-12
Start date
2023-06-01
Completion date
2028-02-01
Last updated
2026-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal Achalasia

Brief summary

Per Oral Endoscopic Myotomy (POEM) is a treatment of choice for achalasia with an excellent safety and efficacy profile. There is a high rate of esophagitis related to gastroesophageal reflux following this procedure. There is no recommendation on the prescription of protein pump inhibitors (PPI) after the procedure and no study has studied the benefit of systematic prescription of PPI after POEM for achalasia. The study authors hypothesize that routine PPI prescribing post-POEM for 12 months would reduce the rate of esophageal acid exposure compared to a symptom-based prescribing strategy.

Interventions

DRUGProtein pump inhibitor therapy systematically

Lansoprazole 30mg once per day

Sponsors

Centre Hospitalier Universitaire de Nīmes
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient with an indication for esophageal POEM for achalasia * Patient with all types of achalasia with Eckardt score \> 3 * The patient must have given their free and informed consent and signed the consent form * The patient must be a member or beneficiary of a health insurance plan

Exclusion criteria

* Patient with contraindications to PPIs * Patient with mediastinal and esophageal neoplasia * Patient with a history of Heller myotomy surgery * Patients requiring any type of anti-reflux valve surgery * The subject is in a period of exclusion determined by a previous study * It is impossible to give the subject informed information * The patient is under safeguard of justice or state guardianship * Patient is pregnant, parturient or breastfeeding

Design outcomes

Primary

MeasureTime frameDescription
Presence of pathological acid reflux between groupsMonth 6According to the Lyon 2018 criteria: Esophagitis grade C or D according to the Los Angeles classification and/or acid exposure \>6% on 24-hour esophageal pH-metry

Secondary

MeasureTime frameDescription
Presence of pathological acid reflux between groupsMonth 12According to the Lyon 2018 criteria: Esophagitis grade C or D according to the Los Angeles classification and/or acid exposure \>6% on 24-hour esophageal pH-metry
Patient quality of life between groupsWeek 6WHOQOL-BREF questionnaire
Patient health-related quality of life between groupsWeek 6Gastroesophageal Reflux Disease Health Related Quality of Life scale (GERD-HRQL)
Quantity of PPI consumed between groupsMonth 3Number of boxes of Lansoprazole consumed as recorded in PPI logbook
Treatment tolerance between groupsMonth 12Occurrence of adverse events as recorded by the doctor during patient interview using a scale of Grade 1 (minor) to Grade 5 (death)
Achalasia symptoms between groupsWeek 6Measured as Eckardt score \>3 (score ranging from 0 (no symptoms)-12 (maximum symptoms))
Pyrosis symptoms between groupsMonth 6Classified according to Rome IV criteria: Acid Reflux, Esophageal Hypersensitivity, Functional Pyrosis, Normal

Countries

France

Contacts

CONTACTAntoine Debourdeau
a-debourdeau@chu-montpellier.fr06.68.31.94.89
PRINCIPAL_INVESTIGATORAntoine Debourdeau

CHU de Nimes

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026